<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209351</url>
  </required_header>
  <id_info>
    <org_study_id>C10-003</org_study_id>
    <nct_id>NCT01209351</nct_id>
  </id_info>
  <brief_title>Effect of Teduglutide on Gastric Emptying in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Dosing, Parallel Group Study to Assess the Effects of Teduglutide (ALX-0600) on Gastric Emptying in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effects of 10 consecutive, daily,&#xD;
      subcutaneous doses of 4 mg of teduglutide as compared with placebo on gastric emptying as&#xD;
      assessed by acetaminophen absorption kinetics in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2010</start_date>
  <completion_date type="Actual">November 8, 2010</completion_date>
  <primary_completion_date type="Actual">November 8, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK log-transformed parameters AUC and CMax</measure>
    <time_frame>Day 10</time_frame>
    <description>The primary objective of this study is to assess the effects of 10 consecutive, daily, subcutaneous doses of 4 mg of teduglutide as compared with placebo on gastric emptying as assessed by acetaminophen absorption kinetics in healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC for each GI blood markers</measure>
    <time_frame>day 10</time_frame>
    <description>The secondary objectives of this study are to assess the effects of subcutaneous dosing of 4 mg of teduglutide administered in single daily doses on the pharmacokinetics of teduglutide on the AUC 3 hours post dose on insulin, glucose, and glucagon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMax</measure>
    <time_frame>Day 10</time_frame>
    <description>The secondary objectives of this study are to assess the effects of subcutaneous dosing of 4 mg of teduglutide administered in single daily doses on the pharmacokinetics of teduglutide on the cMax 3 hours post dose on insulin, glucose, and glucagon.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide</intervention_name>
    <description>teduglutide 4 mg</description>
    <arm_group_label>teduglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed of the nature of the study and have agreed to and are able to read, review,&#xD;
             understand, and sign the informed consent document prior to any screening assessments&#xD;
             being completed.&#xD;
&#xD;
          2. Completed the screening process within 30 days prior to check in&#xD;
&#xD;
          3. Adult males or females age 18 to 45 years in good health as determined by medical&#xD;
             history, physical examination, ECG, and laboratory tests&#xD;
&#xD;
          4. Women who are: (1) post-menopausal; (2) surgically sterilized, OR (3) of childbearing&#xD;
             potential with a negative pregnancy test at screening and check-in and who consent to&#xD;
             use an acceptable method of contraception for the duration of the study and for four&#xD;
             weeks following last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or sensitivity to acetaminophen&#xD;
&#xD;
          2. History of structural abnormality or pathology of the GI tract or diseases/conditions&#xD;
             which affect GI motility including the following:&#xD;
&#xD;
        Gastric, small bowel or colonic resection, Colon cancer or any GI Tract cancer Inflammatory&#xD;
        bowel disease, Irritable bowel disease, Diabetes Mellitus, Gallstones or cholecystectomy,&#xD;
        Appendectomy, hernia repair, benign polypectomy are not excluded, History of Gilbert's&#xD;
        Syndrome 3 History of hepatitis or pancreatitis 4 Evidence of any abnormal hepatobiliary&#xD;
        laboratory parameters (&gt; ULN for serum ALT; AST; ALP; GGT; and/or total, direct or indirect&#xD;
        bilirubin) 5 Serum amylase or lipase above the upper limit of normal 6 Body mass index&#xD;
        (BMI) &gt; 30 kg/m2 7 Intention to use medication that potentially affects GI tract motility 8&#xD;
        History of a viral or bacterial infection, allergy, other inflammatory process or surgery&#xD;
        within 3 weeks of the check-in day.&#xD;
&#xD;
        9 Clinical evidence or history (including that from medical and medication history,&#xD;
        physical examination, laboratory, ECG and any other available test results such as those&#xD;
        from medical imaging studies) of significant cardiovascular, respiratory, renal,&#xD;
        gastrointestinal, hematologic (eg, anemia), neurologic, psychiatric conditions or of any&#xD;
        disease that may interfere with the objectives of the study or with the subject&#xD;
        successfully completing the study 10 Presently taking prescription or over the counter&#xD;
        medication including products containing acetaminophen, vitamins, herbs or dietary&#xD;
        supplements, which cannot be discontinued. Prohibited medications must be discontinued at&#xD;
        least 7 days prior to check-in and all other medications and supplements must be stopped at&#xD;
        least 72 hours prior to check-in.&#xD;
&#xD;
        11 Current or recent history (within 12 months) of drug or alcohol abuse 12 Positive drug&#xD;
        or alcohol screen 13 Current or recent history (within 3 months) of use of tobacco products&#xD;
        14 Positive urine cotinine screen 15 Abnormalities in clinical chemistry, hematology,&#xD;
        urinalysis or in any other laboratory variables 16 Positive results in any of the virology&#xD;
        tests of acute or chronic infectious human immunodeficiency virus (HIV) and hepatitis virus&#xD;
        infections 17 Pregnant or lactating females; positive beta human chorionic gonadotropin&#xD;
        (b-hCG) pregnancy test in females only 18 Special dietary requirements which would preclude&#xD;
        a subject's acceptance of a high fat or high caloric, standardized meal 19 Blood donation&#xD;
        within 4 weeks of the check-in day 20 Participation in another clinical trial with an&#xD;
        investigational drug or device within the last month (if single dose) and at least 3 months&#xD;
        (if multiple dose) or within 10 times the half-life of the respective investigational drug,&#xD;
        whatever is longer, before the screening evaluation. For biologics the minimum period is at&#xD;
        least 6 months or the time of duration of the pharmacodynamic effect or 10 times the&#xD;
        half-life of the respective drug, whatever is longer, before the screening evaluation.&#xD;
&#xD;
        21 Lack of ability or willingness to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>teduglutide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

